{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:11:37Z","timestamp":1792951897352,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11523-018-0552-7","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T07:23:42Z","timestamp":1517815422000},"page":"247-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Induction chemotherapy with the EXTREME regimen in frail patients with locally advanced head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"13","author":[{"given":"Val\u00e9rie","family":"Cochin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"de Mones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Digue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Garcia-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Majoufre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipe","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Daste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"issue":"1","key":"552_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"552_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.oraloncology.2012.06.014","volume":"48","author":"J Ma","year":"2012","unstructured":"Ma J, Liu Y, Huang X-L, Zhang Z-Y, Myers JN, Neskey DM et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol. 2012;48:1076\u201384.","journal-title":"Oral Oncol."},{"key":"552_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"J-P Pignon","year":"2009","unstructured":"Pignon J-P, le Ma\u00eetre A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4\u201314.","journal-title":"Radiother Oncol"},{"key":"552_CR4","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","volume":"31","author":"P Blanchard","year":"2013","unstructured":"Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJC et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31:2854\u201360.","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"552_CR5","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2016.34.15_suppl.6000","volume":"34","author":"L Geoffrois","year":"2016","unstructured":"Geoffrois L, Martin L, Garaud P, Raucourt DD, Miny J, Maingon P et al. Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT\/RT) in patients with N2b\/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2016;34(15_suppl):6000.","journal-title":"J Clin Oncol"},{"key":"552_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695\u2013704.","journal-title":"N Engl J Med."},{"key":"552_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116\u201327.","journal-title":"N Engl J Med."},{"key":"552_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","volume":"21","author":"DJ Adelstein","year":"2003","unstructured":"Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92\u20138.","journal-title":"J Clin Oncol."},{"key":"552_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.2009.23.0425","volume":"28","author":"MS Kies","year":"2010","unstructured":"Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010;28:8\u201314.","journal-title":"J Clin Oncol."},{"key":"552_CR10","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","volume":"28","author":"A Argiris","year":"2010","unstructured":"Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol. 2010;28:5294\u2013300.","journal-title":"J Clin Oncol"},{"key":"552_CR11","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1093\/annonc\/mdu248","volume":"25","author":"HJ Wanebo","year":"2014","unstructured":"Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA et al. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III\/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014;25:2036\u201341.","journal-title":"Ann Oncol."},{"key":"552_CR12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705\u201315.","journal-title":"N Engl J Med."},{"key":"552_CR13","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","volume":"32","author":"EEW Cohen","year":"2014","unstructured":"Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735\u201343.","journal-title":"J Clin Oncol."},{"key":"552_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, O\u2019Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257\u201364.","journal-title":"Lancet Oncol."},{"key":"552_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijrobp.2015.10.019","volume":"94","author":"R Mes\u00eda","year":"2016","unstructured":"Mes\u00eda R, V\u00e1zquez S, Grau JJ, Garc\u00eda-S\u00e1enz JA, Lozano A, Garc\u00eda C et al. A phase 2 open label, single-arm trial to evaluate the combination of cetuximab plus taxotere, cisplatin, and 5-flurouracil as an induction regimen in patients with unresectable squamous cell carcinoma of the head and neck. Int J Radiat Oncol. 2016;94:289\u201396.","journal-title":"Int J Radiat Oncol."},{"key":"552_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1634\/theoncologist.2015-0208","volume":"20","author":"K-W Lee","year":"2015","unstructured":"Lee K-W, Koh Y, Kim S-B, Shin S-W, Kang J-H, Wu H-G et al. A randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer. Oncologist. 2015;20:1119\u201320.","journal-title":"Oncologist"},{"key":"552_CR17","doi-asserted-by":"publisher","first-page":"37297","DOI":"10.18632\/oncotarget.8934","volume":"7","author":"J Fayette","year":"2016","unstructured":"Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A et al. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. Oncotarget. 2016;7:37297\u2013304.","journal-title":"Oncotarget."},{"key":"552_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21\u20138.","journal-title":"Lancet Oncol."},{"key":"552_CR19","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1200\/JCO.2004.00.1990","volume":"23","author":"R Hitt","year":"2005","unstructured":"Hitt R, L\u00f3pez-Pousa A, Mart\u00ednez-Trufero J, Escrig V, Carles J, Rizo A et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636\u201345.","journal-title":"J Clin Oncol."},{"issue":"Suppl 1","key":"552_CR20","doi-asserted-by":"publisher","first-page":"E1271","DOI":"10.1002\/hed.24204","volume":"38","author":"T Sagardoy","year":"2016","unstructured":"Sagardoy T, Fernandez P, Ghafouri A et al. Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up. Head Neck. 2016;38(Suppl 1):E1271\u20136.","journal-title":"Head Neck."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0552-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0552-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0552-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T01:06:02Z","timestamp":1549328762000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0552-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0552-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"5 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}